As global diabetes prevalence continues to rise, insulin production must scale while meeting strict GMP and sterility requirements. This case study explores how industrial insulin manufacturing is designed, from biotechnology to aseptic formulation, and how Boccard supported a major producer in reinforcing formulation capacity.

Discover how E. coli recombinant protein fermentation scale up moves from 5 L glass to a 30 L seed and 150 L main bioreactor, with inline pH/DO/glucose analytics, CIP/SIP and compact centrifuge, sonication and ultrafiltration. A temperature and pH controlled waste inactivation tank enables safe discharge in a limited space. With TEKINBIO™ and Track Advance, teams gain tighter control and traceable scale‑up for reliable industrialisation.